All companies
Visit website
Sollievo Pharmaceuticals
OperatingSollievo Pharmaceuticals, Inc
Healthcare · Founded 2018
Seeking to improve safety for healthcare staff with our first product, Proviza
Post-money valuation ⓘ
$20.0M
As of Dec 2022 · from Sollievo Pharmaceuticals Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$37,982
Across 1 round since 2022
Latest share price
$2.00
Sollievo Pharmaceuticals Common Stock 1 offering price
Financials
FY2020–FY2023 · from SEC filings · hover any figure for its source$0
−$1.2M
2020
$0
−$189K
2021
$0
−$240K
2022
$0
−$76K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
FY2023
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
Net income
-$1,164,009
-$189,478
-$239,558
-$75,851
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$1,157
$153
$60
$60
Accounts receivable
$0
$0
$0
$0
Total assets
$1,157
$153
$89
$60
Short-term debt
$655,821
$772,225
$734,612
$736,824
Long-term debt
$1,180,819
$1,252,890
$1,477,833
$1,524,838
Total liabilities
$1,836,640
$2,025,115
$2,212,445
$2,261,662
Other
Headcount
—
1
1
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$20.0M
post-money
Sollievo Pharmaceuticals Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $38K / $1.1MInvestors 42Post-money $20M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 2 of 4 annual reports (FY2022–FY2025)
42 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001940381Share price $2.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.